BriaCell Therapeutics Corp.

TSX:BCT.TO

Biotechnology

Healthcare
$5.75 +18.88%

+$0.94 today

Market cap
$50.02M
Beta
1.53
P/E (TTM)
-0.3
EPS (TTM)
-$4.23
52W Low $3.68High $20.40

Volume 0.00M

Average 0.01M

BCT.TO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

BriaCell Therapeutics Corp.TSX: BCT.TO

Financing Cash Flow · Q3 FY2026 · quarter ended Apr 2026

Financing cash flow turns negative

Q3 FY2026 financing cash flow was -$107.73K, compared with $14.71M a year earlier. Trailing-twelve-month financing cash flow was $41.33M.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near -$107.73K or moves back toward the trailing-twelve-month quarterly average of $10.33M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
-$107.73K-100.4% QoQ
Last fiscal yearJul 2025
$46M+941.1% YoY
LTMApr 2026
$41.33M+14.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.7%——
1 year+941.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
46M USD
Year-over-year change
+941.1%
4-year CAGR
-8.3%

Financing Cash Flow vs competitors

How BCT.TO compares with its peers on the latest reported figures

No competitor Financing Cash Flow figures are available to compare.

Cash Flow Statement

USD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Net Income(13.82M)(26.84M)(20.3M)(4.93M)(26.63M)
Depreciation & Amortization15.26K15.27K15.27K83.9K107.93K
Deferred Income Tax00000
Stock-Based Compensation1.97M3.07M2.19M1.8M0
Change in Working Capital(2.28M)(391.29K)(3.53M)7.05M(1.93M)
Accounts Receivables9.94K(11.53K)5.23K(732.58K)742.6K
Inventory00000
Accounts Payables(1.41M)249.16K660.46K6.05M(3.93M)
Other Working Capital(886.38K)(628.93K)(4.2M)1.74M1.26M
Other Non-Cash Items6.36M11.66M(2.12M)(28.14M)(58.73K)
Operating Cash Flow(7.75M)(12.48M)(23.74M)(24.13M)(28.51M)
Capital Expenditures000(456.8K)0
Acquisitions (Net)000(225K)0
Purchases of Investments0000(7.74M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow000(681.8K)(7.74M)
Debt Repayment(330.4K)0000
Common Stock Issued51.62M04M4.42M46M
Common Stock Repurchased0(10.17M)(47.29K)00
Dividends Paid00000
Other Financing Activities13.71M6.43M1.59K00
Financing Cash Flow65M(3.74M)3.95M4.42M46M
Effect of Forex Changes0000(84.08K)
Net Change in Cash57.25M(16.23M)(19.79M)(20.39M)9.67M
Free Cash Flow(7.75M)(12.48M)(23.74M)(24.58M)(28.51M)

BriaCell Therapeutics Corp.

TSX:BCT.TO

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.